Complex network and gene ontology in pharmacology approaches: Mapping natural compounds on potential drug target colon cancer network

Current Bioinformatics

Volumn 6, Issue 1, 2011, Pages 44-52

  Bhattacharjee, Biplab ^a   Jayadeepa, R M ^a   Talambedu, Usha ^b   Banerjee, Sanghita ^c   Joshi, Jayadev ^d   Mole, Jilu Princy ^e   Samuel, Joshua ^e   Middha, Sushil Kumar ^b  

^a Institute of Computational Biology   (India)

^b Maharani Lakshmi Ammanni College for Women   (India)

^c INDIAN STATISTICAL INSTITUTE   (India)

^d CSIR INSTITUTE OF GENOMICS AND INTEGRATIVE BIOLOGY   (India)

^e KARUNYA UNIVERSITY   (India)

Author keywords

Chemo preventive drugs; Colon cancer; Gene ontology; Mapping; Systems biology

Indexed keywords

BIOINFORMATICS; COMPLEX NETWORKS; DISEASES; GENES; MAPPING; MOLECULAR BIOLOGY;

CHEMO PREVENTIVE DRUG; COLON CANCER; DRUG TARGETS; GENE ONTOLOGY; HUB NODES; NATURAL COMPOUNDS; ON POTENTIALS; POTENTIAL DRUG TARGETS; PROTEOMICS; SYSTEMS BIOLOGY;

GENE ONTOLOGY;

ARTICLE; COLON CANCER; GENE EXPRESSION; GENE MAPPING; GENE TARGETING; HUMAN; PRIORITY JOURNAL; PROTEOMICS;

EID: 79953851461     PISSN: 15748936     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489311795222400     Document Type: Article

References (107)

1. Cotton FA, Hazen EE Jr, Legg MJ. Staphylococcal nuclease: proposed mechanism of action based on structure of enzymethymidine 3',5'-bisphosphate-calcium ion complex at 1.5-A resolution. Proc Natl Acad Sci USA 1979; 76: 2551-5.
2. Auffray C. Protein subnetwork markers improve prediction of cancer outcome. Mol Syst Biol 2007; 3: 141.
3. Chuang HY, Lee E, Liu YT, Lee D, Ideker T. Network-based classification of breast cancer metastasis. Mol Syst Biol 2007; 3: 140.
4. Ideker T, Sharan R. Protein networks in disease. Genome Res 2008; 18: 644-52.
5. Ideker T, Valencia A. Bioinformatics in the human interactome project. Bioinformatics 2006; 22: 2973-4.
6. Ideker TE. Network genomics. Ernst Schering Res Found Workshop 2007: 89-115.
7. Kalaev M, Smoot M, Ideker T, Sharan R. NetworkBLAST: comparative analysis of protein networks. Bioinformatics 2008; 24: 594-6.
8. Lee E, Chuang HY, Kim JW, Ideker T, Lee D. Inferring pathway activity toward precise disease classification. PLoS Comput Biol 2008; 4: e1000217.
9. Boon K, Osorio EC, Greenhut SF, et al. An anatomy of normal and malignant gene expression. Proc Natl Acad Sci USA 2002; 99: 11287-92.
10. Loging WT, Lal A, Siu IM, et al. Identifying potential tumor markers and antigens by database mining and rapid expression screening. Genome Res 2000; 10: 1393-402.
11. Segal E, Fiedman N, Kaminski N, Regev A, Koller D. From signatures to models: understanding cancer using microarrays. Nat Genet 2005; 37: S38-S45.
12. Martinez-Romero M, Vazquez-Naya JM, Rabunal JR, et al. Artificial intelligence techniques for colorectal cancer drug metabolism: ontology and complex network. Curr Drug Metab 2010; 11: 347-68.
13. Vazquez-Naya JM, Martinez-Romero M, Porto-Pazos AB, et al. Ontologies of drug discovery and design for neurology, cardiology and oncology. Curr Pharm Design 2010; 16: 2724-36.
14. Smith B. Ontology: philosophical and computational. In Floridi L, Ed. The blackwell guide to the philosophy of computing and information, Oxford: Blackwell Publishers 2003.
15. Smith B, Ceusters W, Klagges B, et al. Relations in biomedical ontologies. Genome Biol 2005; 6: R46.
16. Gómez-Pérez A, Fernández-López M, Corcho O. Ontological Engineering: With Examples from the Areas of Knowledge Management, E-Commerce and the Semantic Web. Springer: 2004.
17. Ashburner M, Lewis S. On ontologies for biologists: the Gene Ontology-untangling the web. Novartis Found Symp 2002; 247: 66-80.
18. Stevens R, Goble CA, Bechhofer S. Ontology-based knowledge representation for bioinformatics. Brief Bioinform 2000; 1: 398-414.
19. Kita H, Kato M, Gleich GJ, Abraham RT. Tyrosine phosphorylation and inositol phosphate production: are early events in human eosinophil activation stimulated by immobilized secretory IgA and IgG?. J Allergy Clin Immunol 1994; 94: 1272-81.
20. Gale MJr, Carter V, Parsons M. Cell cycle-specific induction of an 89 kDa serine/threonine protein kinase activity in Trypanosoma brucei. J Cell Sci 1994; 107 (Pt 7): 1825-32.
21. Wheeler-Alm E, Shapiro SZ. Glycosome-associated tyrosinephosphorylated protein in Trypanosoma brucei. Trop Med Parasitol 1993; 44: 281-4.
22. Blake J. Bio-ontologies-fast and furious. Nat Biotechnol 2004; 22: 773-4.
23. Shah NH, Rubin DL, Espinosa I, Montgomery K, Musen MA. Annotation and query of tissue microarray data using the NCI Thesaurus. BMC Bioinformatics 2007; 8: 296.
24. Noy NF, Shah NH, Whetzel PL, et al. BioPortal: ontologies and integrated data resources at the click of a mouse. Nucleic Acids Res 2009; 37: W170-W3.
25. Gusev Y, Schmittgen T, Lerner M, Postier R, Brackett D. Computational analysis of biological functions and pathways collectively targeted by co-expressed microRNAs in cancer. BMC Bioinformatics 2007; 8: S16.
26. Whetzel PL, Parkinson H, Causton HC, et al. The MGED Ontology: a resource for semantics-based description of microarray experiments. Bioinformatics 2006; 22: 866-73.
27. Smith B, Ashburner M, Rosse C, et al. The OBO Foundry: coordinated evolution of ontologies to support biomedical data integration. Nat Biotechnol 2007; 25: 1251.
28. National Center for Biomedical Ontology. BioPortal Website. http://bioportal.bioontology.org (February 19).
29. Moro S, Braiuca P, Deflorian F, et al. Combined target-based and ligand-based drug design approach as a tool to define a novel 3Dpharmacophore model of human A3 adenosine receptor antagonists: pyrazolo [4,3-e]1,2,4-triazolo [1,5-c] pyrimidine derivatives as a key study. J Med Chem 2005; 48: 152-62.
30. Ashburner M, Ball CA, Blake JA, et al. Gene Ontology: tool for the unification of biology. Nat Genet 2000; 25: 25-9.
31. National Cancer Institute. Enterprise Vocabulary Services. http://www.cancer.gov/cancertopics/terminologyresources (February 17).
32. Bodenreider O. The Unified Medical Language System (UMLS): integrating biomedical terminology. Nucleic Acids Res 2004; 32: 267-70.
33. Dheyongera JP, Geldenhuys WJ, Dekker TG, Van der Schyf CJ. Synthesis, biological evaluation, and molecular modeling of novel thioacridone derivatives related to the anticancer alkaloid acronycine. Bioorg Med Chem 2005; 13: 689-98.
34. Lander ES, Linton LM, Birren B, et al. Initial sequencing and analysis of the human genome. Nature 2001; 409: 860-921.
35. Stratton MR, Campbell PJ, Futreal PA. The cancer genome. Nature 2009; 458: 719-24.
36. Kanehisa M, Goto S, Furumichi M, Tanabe M, Hirakawa M. KEGG for representation and analysis of molecular networks involving diseases and drugs. Nucleic Acids Res 2010; 38: D355-D60.
37. Pathguide: the pathway resource list. http://www.pathguide.org (February 19).
38. Luciano JS. PAX of mind for pathway researchers. Drug Discov Today 2005; 10: 937-42.
39. Kanehisa M, Goto S. KEGG: Kyoto encyclopedia of genes and genomes. Nucleic Acids Res 2000; 28: 27-30.
40. Caspi R, Foerster H, Fulcher CA, et al. The MetaCyc Database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res 2008; 36: D623-D31.
41. Lin G, Liu YC, Lin YF, Wu YG. Ortho effects in quantitative structure-activity relationships for acetylcholinesterase inhibition by aryl carbamates. J Enzyme Inhib Med Chem 2004; 19: 395-401.
42. Joshi-Tope G, Gillespie M, Vastrik I, et al. Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 2005; 33: D428-D32.
43. Kayser K, Gabius HJ. Graph theory and the entropy concept in histochemistry. Theoretical considerations, application in histopathology and the combination with receptor-specific approaches. Prog Histochem Cytochem 1997; 32: 1-106.
44. Yamamoto S, Asanuma T, Takagi T, Fukuda KI. The molecule role ontology: an ontology for annotation of signal transduction pathway molecules in the scientific literature. Comp Funct Genomics 2004; 5: 528-36.
45. Mi H, Guo N, Kejariwal A, Thomas PD. PANTHER version 6: protein sequence and function evolution data with expanded representation of biological pathways. Nucleic Acids Res 2007; 35: D247-D52.
46. Morley M, Arcaro M, Burdick J, et al. GenMapDB: a database of mapped human BAC clones. Nucleic Acids Res 2001; 29: 144-7.
47. Demir E, Babur O, Dogrusoz U, et al. PATIKA: an integrated visual environment for collaborative construction and analysis of cellular pathways. Bioinformatics 2002; 18: 996-1003.
48. Okuda S, Yamada T, Hamajima M, et al. KEGG Atlas mapping for global analysis of metabolic pathways. Nucleic Acids Res 2008; 36: W423-W6.
49. Green ML, Karp PD. The outcomes of pathway database computations depend on pathway ontology. Nucleic Acids Res 2006; 34: 3687-97.
50. de La Cruz N, Bromberg S, Pasko D, et al. The Rat Genome Database (RGD): developments towards a phenome database. Nucleic Acids Res 2005; 33: D485-D91.
51. Twigger S, Lu J, Shimoyama M, et al. Rat Genome Database (RGD): mapping disease onto the genome. Nucleic Acids Res 2002; 30: 125-8.
52. Kanehisa M, Araki M, Goto S, et al. KEGG for linking genomes to life and the environment. Nucleic Acids Res 2008; 36: D480-D4.
53. Meneses-Marcel A, Rivera-Borroto OM, Marrero-Ponce Y, et al. New antitrichomonal drug-like chemicals selected by bond (edge)-based TOMOCOMD-CARDD descriptors. J Biomol Screen 2008; 13: 785-94.
54. Alvarez-Ginarte YM, Crespo-Otero R, Marrero-Ponce Y, et al. Chemometric and chemoinformatic analyses of anabolic and androgenic activities of testosterone and dihydrotestosterone analogues. Bioorg Med Chem 2008; 16: 6448-59.
55. Roman C, Saha D, Beauchamp R. TGF-beta and colorectal carcinogenesis. Microsc Res Tech 2001; 52: 450-7.
56. Arnedo MA, Coddington J, Agnarsson I, Gillespie RG. From a comb to a tree: phylogenetic relationships of the comb-footed spiders (Araneae, Theridiidae) inferred from nuclear and mitochondrial genes. Mol Phylogenet Evol 2004; 31: 225-45.
57. Marrero-Ponce Y, Meneses-Marcel A, Rivera-Borroto OM, et al. Bond-based linear indices in QSAR: computational discovery of novel anti-trichomonal compounds. J Comput Aided Mol Des 2008; 22: 523-40.
58. Castillo-Garit JA, Marrero-Ponce Y, Escobar J, Torrens F, Rotondo R. A novel approach to predict aquatic toxicity from molecular structure. Chemosphere 2008; 73: 415-27.
59. Miya M, Nishida M. Use of mitogenomic information in teleostean molecular phylogenetics: a tree-based exploration under the maximum-parsimony optimality criterion. Mol Phylogenet Evol 2000; 17: 437-55.
60. Roldos V, Nakayama H, Rolon M, et al. Activity of a hydroxybibenzyl bryophyte constituent against Leishmania spp. and Trypanosoma cruzi: in silico, in vitro and in vivo activity studies. Eur J Med Chem 2008; 43: 1797-807.
61. Caspi R, Foerster H, Fulcher CA, et al. The MetaCyc Database of metabolic pathways and enzymes and the BioCyc collection of Pathway/Genome Databases. Nucleic Acids Res 2008; 36: D623-31.
62. Caballero J, Fernandez M. Artificial neural networks from MATLAB in medicinal chemistry. Bayesian-regularized genetic neural networks (BRGNN): application to the prediction of the antagonistic activity against human platelet thrombin receptor (PAR-1). Curr Top Med Chem 2008; 8: 1580-605.
63. Duardo-Sanchez A, Patlewicz G, Lopez-Diaz A. Current topics on software use in medicinal chemistry: intellectual property, taxes, and regulatory issues. Curr Top Med Chem 2008; 8: 1666-75.
64. Gonzalez MP, Teran C, Saiz-Urra L, Teijeira M. Variable selection methods in QSAR: an overview. Curr Top Med Chem 2008; 8: 1606-27.
65. Gonzalez-Diaz H. Quantitative studies on Structure-Activity and Structure-Property Relationships (QSAR/QSPR). Curr Top Med Chem 2008; 8: 1554.
66. Gonzalez-Diaz H, Prado-Prado F, Ubeira FM. Predicting antimicrobial drugs and targets with the MARCH-INSIDE approach. Curr Top Med Chem 2008; 8: 1676-90.
67. Helguera AM, Combes RD, Gonzalez MP, Cordeiro MN. Applications of 2D descriptors in drug design: a DRAGON tale. Curr Top Med Chem 2008; 8: 1628-55.
68. Ivanciuc O. Weka machine learning for predicting the phospholipidosis inducing potential. Curr Top Med Chem 2008; 8: 1691-709.
69. Vilar S, Cozza G, Moro S. Medicinal chemistry and the molecular operating environment (MOE): application of QSAR and molecular docking to drug discovery. Curr Top Med Chem 2008; 8: 1555-72.
70. Wang JF, Wei DQ, Chou KC. Drug candidates from traditional chinese medicines. Curr Top Med Chem 2008; 8: 1656-65.
71. Wang JF, Wei DQ, Chou KC. Pharmacogenomics and personalized use of drugs. Curr Top Med Chem 2008; 8: 1573-9.
72. Torrens F, Castellano G. Topological charge-transfer indices: from small molecules to proteins. Curr Proteomics 2009; 6: 204-13.
73. Concu R, Dea-Ayuela MA, Perez-Montoto LG, et al. 3D entropy and moments prediction of enzyme classes and experimentaltheoretic study of peptide fingerprints in Leishmania parasites. Biochim Biophys Acta 2009; 1794: 1784-94.
74. Ivanciuc O. Machine learning quantitative structure-activity relationships (QSAR) for peptides binding to Human Amphiphysin-1 SH3 domain. Curr Proteomics 2009; 4: 289-302.
75. Vilar S, Gonzalez-Diaz H, Santana L, Uriarte E. A network-QSAR model for prediction of genetic-component biomarkers in human colorectal cancer. J Theor Biol 2009; 261: 449-58.
76. Giuliani A, Di Paola L, Setola R. Proteins as Networks: a mesoscopic approach using haemoglobin molecule as case study. Curr Proteomics 2009; 6: 235-45.
77. Chou KC. Pseudo amino acid composition and its applications in bioinformatics, proteomics and system biology. Curr Proteomics 2009; 6: 262-74.
78. Chen J, Shen B. Computational analysis of amino acid mutation: a Proteome wide perspective. Curr Proteomics 2009; 6: 228-34.
79. Zhong WZ, Zhan J, Kang P, Yamazaki S. Gender specific drug metabolism of PF-02341066 in rats--role of sulfoconjugation. Curr Drug Metab 2010; 11: 296-306.
80. Wang JF, Chou KC. Molecular modeling of cytochrome P450 and drug metabolism. Curr Drug Metab 2010; 11: 342-6.
81. Mrabet Y, Semmar N. Mathematical methods to analysis of topology, functional variability and evolution of metabolic systems based on different decomposition concepts. Curr Drug Metab 2010; 11: 315-41.
82. Khan MT. Predictions of the ADMET properties of candidate drug molecules utilizing different QSAR/QSPR modelling approaches. Curr Drug Metab 2010; 11: 285-95.
83. Gonzalez-Diaz H, Duardo-Sanchez A, Ubeira FM, et al. Review of MARCH-INSIDE & complex networks prediction of drugs: ADMET, anti-parasite activity, metabolizing enzymes and cardiotoxicity proteome biomarkers. Curr Drug Metab 2010; 11: 379-406.
84. Gonzalez-Diaz H. Network topological indices, drug metabolism, and distribution. Curr Drug Metab 2010; 11: 283-4.
85. Garcia I, Diop YF, Gomez G. QSAR & complex network study of the HMGR inhibitors structural diversity. Curr Drug Metab 2010; 11: 307-14.
86. Chou KC. Graphic rule for drug metabolism systems. Curr Drug Metab 2010; 11: 369-78.
87. Concu R, Podda G, Ubeira FM, Gonzalez-Diaz H. Review of QSAR models for enzyme classes of drug targets: Theoretical background and applications in parasites, hosts, and other organisms. Curr Pharm Design 2010; 16: 2710-23.
88. Estrada E, Molina E, Nodarse D, Uriarte E. Structural contributions of substrates to their binding to P-Glycoprotein. A TOPS-MODE approach. Curr Pharm Design 2010; 16: 2676-709.
89. Garcia I, Fall Y, Gomez G. QSAR, docking, and CoMFA studies of GSK3 inhibitors. Curr Pharm Design 2010; 16: 2666-75.
90. Gonzalez-Diaz H. QSAR and complex networks in pharmaceutical design, microbiology, parasitology, toxicology, cancer, and neurosciences. Curr Pharm Design 2010; 16: 2598-600.
91. Gonzalez-Diaz H, Romaris F, Duardo-Sanchez A, et al. Predicting drugs and proteins in parasite infections with topological indices of complex networks: theoretical backgrounds, applications, and legal issues. Curr Pharm Design 2010; 16: 2737-64.
92. Marrero-Ponce Y, Casanola-Martin GM, Khan MT, Torrens F, Rescigno A, Abad C. Ligand-based computer-aided discovery of tyrosinase inhibitors. Applications of the TOMOCOMD-CARDD method to the elucidation of new compounds. Curr Pharm Design 2010; 16: 2601-24.
93. Munteanu CR, Fernandez-Blanco E, Seoane JA, et al. Drug discovery and design for complex diseases through QSAR computational methods. Curr Pharm Design 2010; 16: 2640-55.
94. Roy K, Ghosh G. Exploring QSARs with Extended Topochemical Atom (ETA) indices for modeling chemical and drug toxicity. Curr Pharm Design 2010; 16: 2625-39.
95. Speck-Planche A, Scotti MT, de Paulo-Emerenciano V. Current pharmaceutical design of antituberculosis drugs: future perspectives. Curr Pharm Design 2010; 16: 2656-65.
96. Bacilieri M, Moro S. Ligand-based drug design methodologies in drug discovery process: an overview. Curr Drug Discov Technol 2006; 3: 155-65.
97. Randic M, Zupan J, Vikic-Topic D. On representation of proteins by star-like graphs. J Mol Graph Model 2007; 26(1): 290-305.
98. Fernández M, Caballero F, Fernández L, Abreu JI, Acosta G. Classification of conformational stability of protein mutants from 3D pseudo-folding graph representation of protein sequences using support vector machines. Proteins 2008; 70: 167-75.
99. Duarte NC, Becker SA, Jamshidi N, et al. Palsson, B.O. Global reconstruction of the human metabolic network based on genomic and bibliomic data. Proc Natl Acad Sci USA 2007; 104: 1777-82.
100. Koschützki D. CentiBiN Version 1.4.2, 2006.
101. Batagelj V, Mrvar A. Pajek 1.15. 2006.
102. Isaacs FJ, Hasty J, Cantor CR, Collins JJ. Prediction and measurement of an autoregulatory genetic module. Proc Natl Acad Sci USA 2003; 100: 7714-9.
103. Albert R, Jeong H, Barabasi AL. Error and attack tolerance of complex networks. Nature 2000; 406: 378-82.
104. Dobson PD, Cai YD, Stapley BJ, Doig AJ. Prediction of protein function in the absence of significant sequence similarity. Curr Med Chem 2004; 11: 2135-42.
105. Dobson PD, Doig AJ. Predicting enzyme class from protein structure without alignments. J Mol Biol 2005; 345: 187-99.
106. StatSoft. Inc. STATISTICA (data analysis software system), version 6.0, www. statsoft.com.Statsoft, Inc., 6.0; 2002.
107. Akpan N, Caradonna K, Chuenkova MV, Pereira Perrin M. Chagas' disease parasite-derived neurotrophic factor activates cholinergic gene expression in neuronal PC12 cells. Brain Res 2008; 1217: 195-202.